Commitment and Contingencies - Additional Information (Details) - Sutro Biopharma - USD ($) $ in Millions			1 Months Ended
	Nov. 21, 2023	Sep. 28, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Upfront consideration			$ 22.5
Upfront consideration in cash			10.0
Upfront consideration in cash after agreement date			$ 5.0
Number of common stock issued (in shares)			167,780
Fair value on date of settlement			$ 8.0
Accrued payment	$ 50.0
Option exercise price in cash		$ 25.0
Additional milestone payments in cash	$ 60.0
Common Stock
Loss Contingencies [Line Items]
Upfront consideration			$ 7.5